Barclays Lowers Ralliant (NYSE:RAL) Price Target to $52.00

Ralliant (NYSE:RAL) had its target price decreased by analysts at Barclays from $60.00 to $52.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 31.65% from the stock’s current price.

RAL has been the topic of a number of other reports. Oppenheimer dropped their price target on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday. Morgan Stanley restated an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a research note on Friday. Truist Financial dropped their price objective on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research note on Friday. Royal Bank Of Canada reduced their price target on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday. Finally, Weiss Ratings cut shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.50.

Ralliant Trading Up 2.9%

Shares of NYSE RAL opened at $39.50 on Monday. Ralliant has a 52-week low of $37.27 and a 52-week high of $57.02. The stock’s 50 day moving average price is $51.52 and its two-hundred day moving average price is $46.72. The stock has a market capitalization of $4.46 billion and a P/E ratio of 31.10. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Insider Activity

In other Ralliant news, SVP Amir A. Kazmi acquired 2,545 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the acquisition, the senior vice president directly owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin E. Bryant bought 1,250 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were acquired at an average cost of $39.97 per share, with a total value of $49,962.50. Following the completion of the purchase, the director owned 4,653 shares in the company, valued at $185,980.41. This represents a 36.73% increase in their position. The SEC filing for this purchase provides additional information.

Institutional Investors Weigh In On Ralliant

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dodge & Cox bought a new position in shares of Ralliant in the 2nd quarter valued at about $523,571,000. Viking Global Investors LP acquired a new position in Ralliant during the second quarter valued at approximately $257,200,000. State Street Corp bought a new position in Ralliant in the second quarter valued at approximately $213,096,000. Flossbach Von Storch SE acquired a new position in shares of Ralliant during the 2nd quarter worth approximately $198,077,000. Finally, Norges Bank bought a new stake in shares of Ralliant during the 2nd quarter worth approximately $108,453,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.